An observational study in Cardiac Rehabilitation, Heart Failure and Cardiac Arrest (CA), sponsored by Hochgebirgsklinik Davos. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Hochgebirgsklinik Davos · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 149 studies in Heart Failure with a site in Switzerland — 21 open to participants now, 32 under way, 1 of them phase 3. Heart Failure · Switzerland.
Among the 149 studies in Heart Failure with a site in Switzerland, this one is the 3rd largest by planned enrollment of the 46 observational ones that give a count, is one of 10 that started in 2025, is one of 46 observational ones, reaches primary completion later than 30 of the 31 other live ones, and was the 140th registered.
6,332 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.
Browse Heart Failure studies →21 of the 149 studies in Heart Failure with a site in Switzerland are open now. Recruiting first, the newest first:
Biotronik SE & Co. KG · Sites in Switzerland, Australia, Austria and 10 more countries
Ages 18+
Fondazione Don Carlo Gnocchi ETS · Sites in Switzerland, Belgium, Italy and 1 more country
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland, Australia, Bulgaria and 4 more countries
Ages 18+
University Hospital, Basel, Switzerland · Sites in Switzerland, Austria, Bulgaria and 6 more countries
Ages 65+
Bayer · Sites in Switzerland, Austria, Belgium and 14 more countries
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
149 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 25 · Phase 4 17
First in 1983; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 200 across 1,983 observational studies indexed under Heart Failure.
Median enrollment 314 across the 100 interventional studies, 589 across the 46 observational. Of the 105 that completed or were terminated, 38 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
82 of 149 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Hochgebirgsklinik Davos as lead sponsor.
Hochgebirgsklinik Davos has 1 study filed under Heart Failure — fewer than ten, so there is no comparison to draw.
7 of the studies in Heart Failure with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02444416Sebastian CarballoProspective Registry of Acute Heart Failure | 2026-11 |
| NCT06942221University Hospital, Basel, SwitzerlandDigital Solutions in Heart Therapy (DIGNITY) | 2026-12-31 |
| NCT07319039University Hospital, GenevaBreathlessness Patterns in Patients With Cancer, COPD and Heart Failure: an fMRI Feasibility Study | 2027-03-01 |
| NCT06465498Antonio LeidiInvestigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography | 2027-04-30 |
| NCT07852221Insel Gruppe AG, University Hospital BernPatient Selection and Long-Term Outcomes of Pace & Ablate Strategy in Atrial Fibrillation | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 149 studies in Heart Failure with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The RECOVER study, titled Cardiac Rehabilitation Cohort at the Medicine Campus Davos for Exploration of Recovery, is a prospective, non-interventional, monocentric cohort study conducted at the Hochgebirgsklinik Davos. The study is sponsored by Medicine Campus Davos AG and the Kühne Foundation, with an estimated start date in July 2025 and planned completion by December 2034, with the possibility of extension.
The principal investigator of the study is PD Dr. David Niederseer from Hochgebirgsklinik Davos, who also represents the study. The research team includes co-investigators such as Prof. Dr. Stefan Blankenberg and Prof. Dr. Andreas Ziegler from Cardio-CARE, Medicine Campus Davos, as well as Dr. Jan Vontobel from Hochgebirgsklinik Davos.
The study will enroll patients referred to Hochgebirgsklinik Davos for cardiac rehabilitation who provide informed consent. Cardiac rehabilitation is an evidence-based therapy for patients with heart disease, including those who have undergone cardiac procedures or surgeries.
The primary objectives are to evaluate baseline patient characteristics, rehabilitation strategies, predictors of recovery, and clinical outcomes during and after rehabilitation. To support this, a detailed database and biobank will be established to allow for comprehensive phenotyping, extensive clinical assessments, and long-term follow-up.
RECOVER seeks to gain translational insights into how patient-specific factors - such as genetics, plasma, digital and clinical biomarkers, and comorbidities - influence long-term clinical outcomes. The goal is to identify modifiable risk factors to optimize individualized therapeutic approaches in cardiac rehabilitation.
All patients referred to HGK for inpatient CR will be screened for eligibility according to inclusion and exclusion criteria. Study inclusion requires written informed consent, and the study and all -related procedures will be performed according to the Declaration of Helsinki. The study plans to enroll approximately 1'000 patients per year.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Composite of cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke, and hospitalization for heart failure
Outcome assessment will be conducted through a combination of structured telephone follow-up, systematic collection of relevant medical records from the time of inclusion to the follow-up visit, patient-completed questionnaires, and analysis of data from national health and mortality registries.
Time frame: Follow-up 1, 5 and 10 years after inclusion
Incidence of all-cause rehospitalization post cardiac intervention or surgery
All-cause rehospitalization is defined as any unplanned hospital admission, regardless of cause, occurring following the index cardiac intervention or surgery. This includes admissions to any inpatient care facility for diagnostic, therapeutic, or emergency reasons, excluding planned elective procedures or routine follow-up admissions. Data will be obtained through structured follow-up, review of relevant hospital records, and linkage with national health insurance and hospital discharge registries to ensure comprehensive capture of rehospitalization events.
Time frame: Follow-up 1, 5 and 10 years after inclusion
Patient reported quality of life (QoL)
Quality of life will be assessed using the EuroQol 5-Dimension (EQ-5D) questionnaire, a validated patient-reported outcome measure, administered at baseline and follow-up. The EQ-5D index score ranges from less than 0 (indicating health states worse than death) to 1 (perfect health), with higher scores reflecting better health-related quality of life. Changes in index scores will be analyzed to evaluate the effects of cardiac rehabilitation.
Time frame: Follow-up 1, 5 and 10 years after inclusion
Re-surgery / Re-intervention
The incidence of repeat cardiovascular surgery or catheter-based interventions will be recorded within the follow-up period. This includes any planned or unplanned procedures related to the index condition (e.g., valve re-surgery, revascularization) and will be verified through medical records and registry linkage.
Time frame: Follow-up 1, 5 and 10 years after inclusion
New-Onset Atrial Fibrillation
New-onset atrial fibrillation is defined as a first documented episode of AF after the index cardiac intervention or surgery, verified by ECG or rhythm monitoring. Occurrence will be assessed through medical records, telemetry data, and clinical follow-up.
Time frame: Follow-up 1, 5 and 10 years after inclusion
Cognitive Function
Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA), a standardized screening tool that evaluates multiple cognitive domains including memory, attention, executive function, and processing speed. Scores range from 0 to 30, with higher scores indicating better cognitive performance. Assessments will be conducted at baseline and follow-up to detect changes or cognitive decline following the intervention.
Time frame: Follow-up 1, 5 and 10 years after inclusion
Functional Capacity
Functional capacity will be objectively assessed at baseline and discharge using the standardized 6-minute walk test (6MWT). At follow-up, functional status will be evaluated through patient-reported outcomes collected via structured interviews and questionnaires to estimate changes in physical performance and exercise tolerance over time.
Time frame: Follow-up 1, 5 and 10 years after inclusion
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Aug 2035, 120 months after the start.
Of 794 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 99. This study's planned 120 months is above that.
Counting every sponsor, half of 976 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.